Clinical Data

Clinical Data develops and commercializes treatments for central nervous system and cardiovascular diseases, focusing on the development and commercialization of therapeutic drugs with two compounds in the central nervous system and cardiovascular disease areas. The company's late-stage candidate drug is vilazodone, a dual-action potent selective serotonin reuptake inhibitor and partial agonist of the serotonin receptor 1A (5-HT1A), used for treating major depressive disorder (MDD). The company’s second late-stage candidate drug is apadenoson, branded as Stedivaze, a selective adenosine receptor 2A (AR2A) agonist and coronary vasodilator currently in Phase III clinical development for nuclear single-photon emission computed tomography (SPECT) myocardial perfusion imaging.